Virios Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
2.830
-1.045 (-26.97%)
At close: Oct 9, 2024, 4:00 PM
2.570
-0.260 (-9.19%)
Pre-market: Oct 10, 2024, 5:10 AM EDT

Virios Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Cash & Equivalents
3.023.327.0314.0129.80.31
Upgrade
Cash & Short-Term Investments
3.023.327.0314.0129.80.31
Upgrade
Cash Growth
-34.20%-52.82%-49.81%-52.99%9530.55%930.39%
Upgrade
Other Receivables
-----0
Upgrade
Receivables
-----0
Upgrade
Prepaid Expenses
0.390.711.181.351.590.01
Upgrade
Other Current Assets
0.230.140.160.420.09-
Upgrade
Total Current Assets
3.644.178.3715.7831.470.32
Upgrade
Total Assets
3.644.178.3715.7831.470.32
Upgrade
Accounts Payable
0.220.110.570.350.370.04
Upgrade
Accrued Expenses
0.280.250.470.921.161.59
Upgrade
Total Current Liabilities
0.50.361.041.281.531.62
Upgrade
Long-Term Debt
-----3.64
Upgrade
Total Liabilities
0.50.361.041.281.535.26
Upgrade
Common Stock
0000012.6
Upgrade
Additional Paid-In Capital
67.2465.5763.558.4357.91-
Upgrade
Retained Earnings
-63.81-61.47-56.17-43.93-27.97-17.62
Upgrade
Treasury Stock
-0.3-0.3----
Upgrade
Total Common Equity
3.143.817.3314.529.94-5.02
Upgrade
Shareholders' Equity
3.143.817.3314.529.94-4.94
Upgrade
Total Liabilities & Equity
3.644.178.3715.7831.470.32
Upgrade
Total Debt
-----3.64
Upgrade
Net Cash (Debt)
3.023.327.0314.0129.8-3.33
Upgrade
Net Cash Growth
-34.20%-52.82%-49.81%-52.99%--
Upgrade
Net Cash Per Share
3.754.4215.8842.04151.18-17.22
Upgrade
Filing Date Shares Outstanding
1.110.770.730.330.330.19
Upgrade
Total Common Shares Outstanding
1.110.770.730.330.330.19
Upgrade
Working Capital
3.143.817.3314.529.94-1.3
Upgrade
Book Value Per Share
2.824.949.9943.5290.13-25.96
Upgrade
Tangible Book Value
3.143.817.3314.529.94-5.02
Upgrade
Tangible Book Value Per Share
2.824.949.9943.5290.13-25.96
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.